Ravindra, Kodihalli C.
Vaidya, Vishal S.
Wang, Zhenyu
Federspiel, Joel D. http://orcid.org/0000-0002-2010-0071
Virgen-Slane, Richard
Everley, Robert A.
Grove, Jane I. http://orcid.org/0000-0002-9950-7201
Stephens, Camilla http://orcid.org/0000-0002-0796-9610
Ocana, Mireia F.
Robles-Díaz, Mercedes
Isabel Lucena, M. http://orcid.org/0000-0001-9586-4896
Andrade, Raul J. http://orcid.org/0000-0002-1565-0757
Atallah, Edmond http://orcid.org/0000-0002-7341-9174
Gerbes, Alexander L.
Weber, Sabine
Cortez-Pinto, Helena http://orcid.org/0000-0002-8537-8744
Fowell, Andrew J.
Hussaini, Hyder
Bjornsson, Einar S.
Patel, Janisha
Stirnimann, Guido http://orcid.org/0000-0003-3447-264X
Verma, Sumita
Elsharkawy, Ahmed M.
Griffiths, William J. H.
Hyde, Craig http://orcid.org/0000-0002-6939-287X
Dear, James W. http://orcid.org/0000-0002-8630-8625
Aithal, Guruprasad P. http://orcid.org/0000-0003-3924-4830
Ramaiah, Shashi K.
Article History
Received: 2 June 2022
Accepted: 16 February 2023
First Online: 3 March 2023
Competing interests
: K.C.R., V.S.V., Z.W., J.D.F., V.S.R., R.E., M.F.O., C.H., and S.K.R. are employed by Pfizer. G.P.A. has served as a consultant and an advisory board member for Pfizer Inc, Inventiva Pharma, GlaxoSmithKline and KaNDy Therapeutics; he has been a consultant to BerGenBio ASA, Median Technologies, FRACTYL, Amryt Pharmaceuticals and AstraZeneca; and has given presentations on behalf of Roche Diagnostics and Medscape. A.G.: stockholder MetaHeps GmbH and owner of IP. E.S.B. is a member of the hepatic safety committee for Galmed pharmaceuticals in the Armor study. H.C.P. lectures and advisory board fees from Intercept, Orphalan, Novo Nordisk, Roche Portugal and EISAI. S.V. has served as a consultant for Abbvie and Gilead Sciences, and given presentations on behalf of Gilead Sciences, Abbvie and Dr Falk. J.W.D. is the Chief Investigator on the ALBATROSS and POP Trials funded by Egetis Therapeutics. A.J.F. is a consultant and advisory board member for Gilead Sciences, Dr Falk Pharma and Accelerated Enrollment Solutions and has given presentations on behalf of Intercept Pharmaceuticals. A.M.E. has been a consultant for GSK, SOBI and Gilead. The remaining authors declare no competing interests.